KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Gross Profit (2016 - 2025)

Historic Gross Profit for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to $173.1 million.

  • Supernus Pharmaceuticals' Gross Profit rose 950.75% to $173.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $603.9 million, marking a year-over-year increase of 402.2%. This contributed to the annual value of $583.9 million for FY2024, which is 1148.83% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Gross Profit of $173.1 million as of Q3 2025, which was up 950.75% from $148.6 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Gross Profit high stood at $173.1 million for Q3 2025, and its period low was $114.5 million during Q2 2023.
  • For the 5-year period, Supernus Pharmaceuticals' Gross Profit averaged around $139.4 million, with its median value being $142.1 million (2021).
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 2347.82% in 2023, then soared by 3139.37% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Gross Profit stood at $142.1 million in 2021, then grew by 1.63% to $144.4 million in 2022, then rose by 0.22% to $144.7 million in 2023, then increased by 2.33% to $148.1 million in 2024, then rose by 16.94% to $173.1 million in 2025.
  • Its Gross Profit stands at $173.1 million for Q3 2025, versus $148.6 million for Q2 2025 and $134.1 million for Q1 2025.